On May 23, 2025, Boston Scientific hosted the national launch of its Vercise Genus™ Deep Brain Stimulation (DBS) System during the 14th Annual Meeting of the Asian-Australasian Society for Stereotactic and Functional Neurosurgery (AASSFN) in China. The system’s debut marks a significant milestone for Parkinson’s care in the region, offering patients a more precise and individualized treatment pathway.

The event brought together leading neurologists and neurosurgeons from China and abroad, who witnessed the official release and shared firsthand experiences with the device. Early adopters praised three core strengths of the Vercise Genus system:

• Precision Targeting: With directional lead technology and MICC (Multiple Independent Current Control), physicians can “shape” stimulation fields, enabling targeted therapy while minimizing side effects.

• Real-Time Visualization: An advanced programming interface allows doctors to visualize brain structures and stimulation effects, reducing programming time by up to 56% and improving treatment accuracy.

• Extended Battery Life: The rechargeable implantable pulse generator (IPG) lasts up to 25 years, reducing surgical risks and supporting long-term stability.

Zhouli Zhu, Senior Director at Boston Scientific China, emphasized the strategic value of the launch: “Vercise Genus was selected for China’s national ‘innovation fast track’ in 2021. As the only system in China with a four-channel IPG, it supports personalized solutions for diverse Parkinson’s symptoms. We’re proud to contribute to the country’s growing precision medicine ecosystem.”

The nationwide rollout reflects Boston Scientific’s continued commitment to advancing neuromodulation innovation and delivering long-term value for patients and clinicians across China.

May 23, 2025, MedChina